Deadline Alert: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Capricor Therapeutics faces a class action securities fraud lawsuit after the FDA criticized the company's statistical analysis methods for its Deramiocel cell therapy trial. The FDA's briefing documents questioned the scientific justification for data conversion methods and concluded the benefit-risk assessment was unfavorable. Following the FDA's concerns and an advisory committee's 9-3 vote against efficacy, Capricor's stock plummeted 62% on July 27, 2026. Investors who purchased shares between December 17, 2025 and July 26, 2026 can file lead plaintiff motions by September 28, 2026.